Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

udies designed to evaluate the dose, toxicity, biologic response, and preliminary clinical response of Dacogen alone and in combination with hyperCVAD, in patients with relapsed/refractory ALL were presented on Saturday, June 2, 2007. Patients were treated with intravenous Dacogen administered daily for five days every other week (starting at 100 mg/m2 per course) with 7 of 13 patients subsequently retreated with Dacogen (starting at 25 mg/m2 per course) and given hyperCVAD every three to four weeks. Both agents were started on Day 1. Two patients had complete bone marrow response on Dacogen alone with one of these patients also having a complete response except for platelets (CRp) with subsequent hyperCVAD therapy. Two additional patients who also received combination therapy had a complete response (CR). One of the responding patients received a successful allogeneic stem cell transplant. Correlative studies on patient peripheral blood samples demonstrated hypomethylation and hematological control. No significant Grade 3 or Grade 4 drug related non-hematological toxicities were observed.

Gliadel(R) Wafer

Retrospective Data on the Overall Survival of Patients with Glioblastoma Treated with Gliadel Wafer Implantation as Part of Multimodal Therapy

The results of a retrospective analysis to assess the survival of patients treated with rotational multi-agent chemotherapy compared to those who received chemotherapy together with Gliadel Wafer were presented in a poster discussion on Monday June 4, 2007. Eighty-five patients with primary glioblastoma multiforme received surgery with (n=36) or without (n=49) Gliadel implantation followed by radiotherapy and concurrent temozolomide (TMZ) plus one year of adjuvant rotational multi-agent chemotherapy (lomustine (CCNU), TMZ, and irinotecan), consisting of two cycles of each agent. After a median follow-up of 132 weeks, the group that received Gliadel had an extended median survival of 89.4 weeks (95% CI,
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:5/1/2015)... CITY, Calif. , May 1, 2015  AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that Timothy E. Morris , chief financial ...  Details of the events are as follows: ... May 5 Location:  The Omni Berkshire Place, ...
(Date:4/30/2015)... MOUNTAIN VIEW, Calif., April 30, 2015 Omnicell, Inc. ... and supply management solutions to healthcare systems, today announced ... GAAP results: Revenue for the first quarter ... 14.2% from the first quarter of 2014, and down ... 2014. First quarter 2015 net income as ...
(Date:4/30/2015)...   Regulus Therapeutics Inc . (NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that it ... ended March 31, 2015 on Thursday, May 7, 2015, ... Regulus will host a conference call and webcast on ... Time to discuss its first quarter 2015 financial results ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... CITY , Feb. 5 (Nasdaq: WHRT ) ... circulatory systems, announced today that on February 4, 2010 , ... to serve as a director of the Company.  Mr. Jones ... of the Board of Directors. , Mr. Jones began his ...
... , WOODCLIFF LAKE, N.J. , Feb. 5 ... Drug Administration (FDA) issued a complete response letter regarding the ... for the prevention of nausea and vomiting associated with highly- ... an agency-wide restriction on foreign travel in India , ...
Cached Medicine Technology:World Heart Corporation Announces the Election of a New Director 2Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film 2Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film 3
(Date:5/2/2015)... ProText Kinetic 2 is a set of ... Pro X. ProText Kinetic 2 features 40 animation ... Pro X . Easily create interactive text videos without ... ProText Kinetic 2. , Using ProText Kinetic is as easy ... Kinetic presets in the FCPX timeline. Playback the default ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured on ... features the latest and coolest technology products available to ... for NewsWatch, conducted the review and shared with viewers ... Music is an important part of people’s lives – ... the royal treatment. Peachtree Audio does just that with ...
(Date:5/2/2015)... TX (PRWEB) May 02, 2015 ... skin laxity issues of the face, neck and ... new concept with real potential for the success ... by the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s ... FACOG, FACS, ACGE, concluded that ThermiGyn’s temperature controlled ...
(Date:5/1/2015)... IDLife LLC, a health and wellness ... the addition of its newest partner and fitness celebrity, ... athlete, growing up in gymnastics and competitive diving, but ... a personal trainer and helping others achieve their fitness ... TV shows highlighting her stunning physique and unique training ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... The American Red Cross,announced today that J. ... of,Executive Vice President for the organization,s Biomedical Services., ... largest blood collection,organizations. Each year the American Red ... distributes around 9.5 million blood products to,patients at ...
... ARLINGTON, Va., Jan. 8 The American,Association for ... fraud announced today in another of a series of ... Services (CMS) on the same,subject. The Association continues to ... in the durable medical equipment,(DME) sector. At the same ...
... - Net revenue projected to grow 20 percent in 2008 ... milestones for the DPP-4 ... - EPS expected to grow 36 percent in 2008, ... 2007 guidance and reported its projected,financial guidance for 2008., PPD anticipates that ...
... Use May Be Associated with Reduced Cancer Risk ... be at lower risk for developing cancer, especially lung ... directly prevent cancer. , Laboratory studies have shown that ... observational studies has been inconsistent. , To investigate ...
... carriers , , TUESDAY, Jan. 8 (HealthDay News) -- Not ... show the same risk for developing breast cancer. , ... risk among families carrying the mutations, indicating that the ... factors. , "Risk among carriers varies considerably, and, if ...
... dialysis patients shows that although U.S. residents have the ... their prescription drugs are far less likely to take ... research from the University of Michigan School of Public ... that high out-of-pocket drug costs are only a partial ...
Cached Medicine News:Health News:American Red Cross Announces New Leader for Biomedical Services 2Health News:Medicare Anti-Fraud Measures are Way Overdue, Says Durable Medical Equipment Industry 2Health News:Medicare Anti-Fraud Measures are Way Overdue, Says Durable Medical Equipment Industry 3Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 2Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 3Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 4Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 5Health News:Other highlights in the Jan. 8 JNCI 2Health News:Other highlights in the Jan. 8 JNCI 3Health News:Other highlights in the Jan. 8 JNCI 4Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 3Health News:Americans pay the most for prescription drugs and still don't take them 2
... The RX600 is a versatile, fully ... range of built-in traction facilities, a powered ... make it extremely versatile too. ,<br.,In fact ... general surgery as it is for traction ...
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator. , ,Most Appropriate for the Proximal Femur, Metatarsal/Tar...
... OrthoVision Orthopedic and Fracture Table is ... It provides flexible, easy to use, ... and reparative orthopedic procedures. Radiolucent abductor ... post provide exceptional imaging capability. OrthoVision ...
... provides a non-invasive therapy for the ... of fresh fracture healing that you ... daily, or as prescribed by your ... fracture to be sufficiently healed to ...
Medicine Products: